Candel Therapeutics (CADL)
(Delayed Data from NSDQ)
$5.84 USD
-0.12 (-2.01%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $5.84 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Candel Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
CADL 5.84 -0.12(-2.01%)
Will CADL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CADL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CADL
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know
Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?
CADL: What are Zacks experts saying now?
Zacks Private Portfolio Services
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
Best Momentum Stocks to Buy for May 19th
New Strong Buy Stocks for May 19th
Other News for CADL
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference | CADL ...
Candel Therapeutics (CADL) Secures EMA Orphan Status for Pancreatic Cancer Treatment | CADL ...
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of ...
Candel Therapeutics receives EMA Orphan Designation for CAN-2409
ASML, J B Hunt Transport And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session